Article Text

Download PDFPDF
Authors’ response: metformin and risk of hepatocellular carcinoma—a study focused on anti-diabetic agents
  1. Chun-Ying Wu1,
  2. Hsiao-Ping Chen2
  1. 1 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
  2. 2 Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan
  1. Correspondence to Professor Chun-Ying Wu, Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 155, Sec. 2, Linong Street, Taipei 112, Taiwan; chun{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Singh et al 1 for their letter2 commenting on our recent paper.3 The authors briefly summarised current evidence regarding the chemopreventive effects of statins on hepatocellular carcinoma (HCC) and noted the lack of analyses on the role of statins in HCC in our study.

We agree that the use of statins was found to be associated with a reduced risk of HCC according to previous studies.3 However, not only statins but also non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, thiazolidinediones, antiviral agents, etc, were all reported to be associated with a …

View Full Text


  • Contributors CYW and HPC replied the letter cooperatively.

  • Funding This research received a specific grant from Taiwan's National Health Research Institutes, grant number PH-100-PP54, that allowed the hiring of a research assistant and provided access to the National Health Insurance Research Database.

  • Competing interests None.

  • Ethics approval Taiwan's National Health Research Institutes.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles